The Oncology Market Research presents an intensive analysis of the global oncology pharmaceuticals and therapeutics market. These market researc...
The Oncology Market Research presents an intensive analysis of the global oncology pharmaceuticals and therapeutics market. These market research reports help to identify and evaluate the market with respect to cancer drugs, vaccines and therapies currently available in the market and in the pipeline. The studies carried out in these research reports are classified into a number of categories so that it becomes easier for you to have a complete knowledge of the oncology industry. These in-depth research reports help you to assess comprehensively each of the market segmentation with respect to market restraints, drivers and opportunities that is driving the market revenues and trend. In addition to this, these research reports facilitate to measure and calculate the market revenues for each of the micro markets with respect to vaccines, drugs and therapy revenues accredited to respective geographies. These market research reports not only analyze and grasp the core competency of the market players by profiling the companies with respect to their product offering, target market, revenues, pricing, patents, recent developments and pipeline products, they also aid in understanding the competitive scenario by following an analytical strategy trend such as alliances, joint ventures, mergers & acquisitions etc. in the industry amongst the leading players.
The Oncology Market Research reports suggest that the oncology market is likely to continue generating lofty revenues and noteworthy profitability in the coming years. There has been an increase in the sales of the leading cancer drugs throughout the world. The future of the major players in the oncology market is highly promising, particularly with the introduction of more-personalized molecular medicine which promises better effectiveness and safety in the treatment of cancer. The oncology industry boasts of having more products in the development pipeline than in any other - with more than four dozen new oncology products to be launched in the near future. The oncology market is seeing many new players entering the market while the established pharma companies are refurbishing themselves so as to tap the up-coming opportunities.
The oncology market is all set to grow steadily due to a number of factors, which includes availability of new treatments, the aging population, the sorting out of the genetics behind cancer, and the reality that cancer is a major disease with many variations. These research reports portray that the growth in the oncology market is projected to be driven by escalating sales of existing market targeted agents and by sales of new targeted agents to be introduced to the market in the near future.
The oncology market research reports reveal that an entirely new phenomenon in the market is crowding and it is changing the economics of the business. Controller and technology evaluators are raising the bar for approval. With the power that comes from having treat¬ment options and the demands that come from rising total costs, patients are seeking to manage utilization and price. Moreover, a recent trend is seen with physicians who are becoming more selec¬tive in their therapy decisions.
According to the research reports, cancer R&D accounts for a huge share of the budget and the number of projects and is the driving force behind a number of biotechnology companies. There are several Avastin, Gleevec and Herceptin follow-up drugs in Phase III trials. The commercial hit, Gleevec has piloted 3 approved follow-up drugs and additional one Brivanib from BMS filed for FDA approval. Roche and Genentech are the leading cancer companies by sales and R&D. Novartis, Amgen, Astra Zeneca, BMS and Pfizer are amongst the other leading cancer companies by sales and R&D. In India, companies such as Natco Pharma, Fresenius Kabi Oncology (formerly Dabur Pharma), Sun Pharma, Dr Reddy’s Labs and Panacea Biotec are dominating the oncology market.